Coagulation disorders during CRS of a BCMA targeted CAR T cell therapy in relapsed/refractory multiple myeloma: Periodic results of a phase I clinical trial

被引：0
|
作者：
Shao, Mi [1 ]
Hu, Yongxian [1 ]
Xu, Huijun [1 ]
Zhang, Yanlei [1 ]
Cui, Jiazhen [1 ]
Huang, He [1 ]
机构：
[1] Zhejiang Univ, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China
来源：
BONE MARROW TRANSPLANTATION | 2019年 / 54卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
O053
引用
收藏
页码：45 / 46
页数：2
相关论文
共 50 条
  • [1] APRIL CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Phase I Clinical Trial
    Li, Wenxiao
    Hu, Yongxian
    Zhang, Mingming
    Lai, Xinyi
    Zhao, Mengyu
    Fu, Shan
    Hong, Ruimin
    Chang, Alex H.
    Huang, He
    BLOOD, 2024, 144 : 7229 - 7229
  • [2] Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial
    Mailankody, Sham
    Ghosh, Arnab
    Staehr, Mette
    Purdon, Terence J.
    Roshal, Mikhail
    Halton, Elizabeth
    Diamonte, Claudia
    Pineda, John
    Anant, Pavan
    Bernal, Yvette
    Wills, Analisa
    Korde, Neha
    Lendvai, Nikoletta
    Lesokhin, Alexander M.
    Hassoun, Hani
    Hultcrantz, Malin
    Landau, Heather J.
    Shah, Gunjan L.
    Scordo, Michael
    Chung, David J.
    Lahoud, Oscar B.
    Khattar, Pallavi
    de larrea, Carlos Fernandez
    Gao, Qi
    Jungbluth, Achim
    Park, Jae H.
    Curran, Kevin J.
    Sauter, Craig S.
    Palomba, Maria Lia
    Senechal, Brigitte
    Wang, Xiuyan
    Dogan, Ahmet
    Giralt, Sergio
    Riviere, Isabelle
    Landgren, Ola
    Brentjens, Renier J.
    Smith, Eric L.
    BLOOD, 2018, 132
  • [3] Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-targeted CAR T therapy
    Van Oekelen, Oliver
    Mouhieddine, Tarek
    Pan, Darren
    Metzger, Megan
    Agte, Sarita
    Aleman, Adolfo
    Melnekoff, David
    Lancman, Guido
    Lagana, Alessandro
    Richard, Shambavi
    Sanchez, Larysa
    Richter, Joshua
    Cho, Hearn Jay
    Chari, Ajai
    Jagannath, Sundar
    Parekh, Samir
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S38 - S38
  • [4] Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial
    Shi, Ming
    Wang, Jiaojiao
    Huang, Hongming
    Liu, Dan
    Cheng, Hai
    Wang, Xu
    Chen, Wei
    Yan, Zhiling
    Sang, Wei
    Qi, Kunming
    Li, Depeng
    Zhu, Feng
    Li, Zhenyu
    Qiao, Jianlin
    Wu, Qingyun
    Zeng, Lingyu
    Fei, Xiaoming
    Gu, Weiying
    Miao, Yuqing
    Xu, Kailin
    Zheng, Junnian
    Cao, Jiang
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [5] A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia
    Li, Chunrui
    Cao, Wenyue
    Que, Yimei
    Wang, Qiuxiang
    Xiao, Yi
    Gu, Chaojiang
    Wang, Di
    Wang, Jue
    Jiang, Lijun
    Xu, Hao
    Xu, Jinhuan
    Zhou, Xiaoxi
    Hong, Zhenya
    Wang, Na
    Huang, Liang
    Zhang, Shangkun
    Chen, Liting
    Mao, Xia
    Xiao, Min
    Zhang, Wei
    Meng, Li
    Cao, Yang
    Zhang, Tongcun
    Li, Jian
    Zhou, Jianfeng
    CLINICAL AND TRANSLATIONAL MEDICINE, 2021, 11 (03):
  • [6] CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
    Xu, Yang
    Zhang, Xuzhao
    Xin, Dijia
    Zhang, Jiawei
    Wang, Luyao
    Fan, Yili
    Chen, Boxiao
    Lei, Wen
    Qiu, Xi
    Jiang, Huawei
    Xiao, Xibin
    Huang, Liansheng
    Yu, Jiandong
    Yang, Xin
    Yang, Wenjun
    Zhu, Jiangao
    Qian, Wenbin
    CANCER IMMUNOLOGY RESEARCH, 2025, 13 (01) : 23 - 34
  • [7] CD27-Armored BCMA-CAR T Cell (CBG-002) Therapy for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
    Xu, Yang
    Zhang, Xuzhao
    Xin, Dijia
    Zhang, Jiawei
    Wang, Luyao
    Fan, Yili
    Chen, Boxiao
    Lei, Wen
    Qiu, Xi
    Jiang, Huawei
    Xiao, Xibin
    Huang, Liansheng
    Yang, Wenjun
    Zhu, Jiangao
    Qian, Wenbin
    BLOOD, 2023, 142
  • [8] A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed/refractory multiple myeloma: results from phase I clinical trials
    Yang, Min
    Zhang, Wenhao
    Yu, Kang
    Wang, Peng
    Jiang, Hua
    Chen, Linjun
    Meng, Haitao
    Weng, Yiqin
    Tao, Rong
    Huang, Xin
    Xing, Chongyun
    Wang, Huamao
    Wan, Jiangbo
    Wang, Shasha
    Dai, Lihui
    Hendrix, Amanda Y.
    Xiao, Jun
    Wang, Wei
    Ma, Hong
    Hao, Siguo
    Jin, Jie
    Li, Zonghai
    Jiang, Songfu
    HAEMATOLOGICA, 2022, 107 (08) : 1960 - 1965
  • [9] GPRC5D-targeted CAR-T cell therapy in patients with relapsed or refractory multiple myeloma progressing after or refractory to BCMA CAR-T cell therapy: updated eesults from a phase 2 clinical trial
    Xia, Jieyun
    Li, Zhenyu
    Li, Hujun
    Yan, Zhiling
    Xu, Mengdi
    Xu, Kailin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S5 - S6
  • [10] Clinical Responses and Pharmacokinetics of fully human BCMA Targeting CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma
    Li, Chunrui
    Zhou, Xiaoxi
    Wang, Jue
    Hu, Guang
    Yang, Yongkun
    Meng, Li
    Hong, Zhenya
    Chen, Liting
    Zhou, Jianfeng
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E23 - E24
12345